Zhitong's disclosure of shareholders' rights in Hong Kong stocks
Written byAInvest Visual
Sunday, Sep 1, 2024 8:10 pm ET1min read
W--
According to the data of Zhitong Finance APP, Cstone Pharma Group (02005), Meituan-W (03690), Kangz Pharmaceutical (00867), Power Development (01277), and DreamSky (01119) made the latest shareholder rights disclosure on September 2, 2024.
| Stock Name | Name of Institution | Nature | Previous Holding | Current Holding | Holding Ratio |
|---|---|---|---|---|---|
| Cstone Pharma Group (02005) | China Pharmaceutical Company Limited | Good Ware | 833 million shares | 835 million shares | 28.12% (latest) 28.05% (previous) |
| Meituan-W (03690) | Mu Rongjuan | Good Ware | 44.9255 million shares | 58.3211 million shares | 1.03% (latest) 0.80% (previous) |
| Cstone Pharma Group (02005) | Qu Jiguang | Good Ware | 1.118 billion shares | 1.12 billion shares | 37.72% (latest) 37.65% (previous) |
| Meituan-W (03690) | Mu Rongjuan | Good Ware | 80.7212 million shares | 67.3345 million shares | 11.55% (latest) 13.53% (previous) |
| Kangz Pharmaceutical (00867) | Lin Gang | Good Ware | 1160 million shares | 1160 million shares | 47.55% (latest) 47.53% (previous) |
| Power Development (01277) | Gu Wenzhong | Good Ware | 8.1197 million shares | 8.8977 million shares | 0.11% (latest) 0.10% (previous) |
| Create Dream (01119) | Chen Xiangyu | Good Ware | 266 million shares | 266 million shares | 15.76% (latest) 15.73% (previous) |
| Kangz Pharmaceutical (00867) | Treasure Sea Limited | Good Ware | 1160 million shares | 1160 million shares | 47.55% (latest) 47.53% (previous) |
Note: The change in the number of shares held may be caused by factors such as rights issue, consolidation, and split, so please pay attention to distinguishing the actual situation.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
Comments
No comments yet